Abstracts tagged "inflammatory arthritis and morbidity and mortality"

Abstract Number: 212 • 2018 ACR/ARHP Annual Meeting
Mortality and Causes of Death in Patients with Inflammatory Arthritis in Hong Kong over 20 Years
Tommy Tsang Cheung, Simon Man Fung Tsoi, Bernard Man Yung Cheung and Chak Sing Lau, Medicine, The University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Patients with inflammatory arthritis have a higher mortality than the general population due to increased risks of cardiovascular diseases, infection and cancer. As the…
Abstract Number: 2544 • 2012 ACR/ARHP Annual Meeting
Widening Gap Between Cardiovascular Specific Mortality in Patients with Inflammatory Polyarthritis Compared to the General Population?
Alexander J. Warner¹, Jh Humphreys², Mark Lunt³, Tarnya Marshall⁴, Deborah P. M. Symmons⁵ and Suzanne Verstappen⁶, ¹Manchester Academic Health Sciences Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ²Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit,, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, ⁵Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit,, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Background/Purpose: Cardiovascular (CVD) mortality rates are raised in patients with inflammatory polyarthritis (IP) but have been shown to be falling in the general population. This…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].